Search Results



Your search for Geoffrey R. Oxnard, MD matches 9 pages

Showing 1 - 9


lung cancer

Dacomitinib vs Gefitinib in Advanced NSCLC: Improving Upon Established First-Line Targeted Therapy

THE RESULTS FROM the ARCHER 1050 study—reported by Wu et al1 and reviewed in this issue of The ASCO Post—highlight the recent optimism about improved outcomes in metastatic non–small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFR) gene. This trial...

lung cancer

Bright Future for Osimertinib in EGFR T790M–Positive Lung Cancer

The AURA3 study—reported by Mok and colleagues and reviewed in this issue of The ASCO Post—confirms the dramatic activity of osimertinib (Tagrisso) in patients with advanced epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) and acquired resistance to prior EGFR...

lung cancer

Plasma vs Tissue Genotyping and Outcomes With Osimertinib in Advanced Non–Small Cell Lung Cancer

Patients with advanced non–small cell lung cancer (NSCLC) positive for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor T790M resistance mutation on a plasma assay had similar outcomes with the EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) as did those who were positive ...

lung cancer

Plasma vs Tissue Genotyping and Outcomes With Osimertinib in Advanced Non–Small Cell Lung Cancer

Patients with advanced non–small cell lung cancer (NSCLC) positive for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor T790M resistance mutation on a plasma assay had similar outcomes with the EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) as did those who were...

2016 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...

lung cancer

Validation of Rapid Plasma Genotyping for Detecting EGFR and KRAS Mutations in Advanced Lung Cancer

As reported in JAMA Oncology, Sacher et al have prospectively validated a plasma droplet digital polymerase chain reaction (ddPCR) assay for detecting common EGFR and KRAS mutations in patients with advanced nonsquamous non–small cell lung cancer. Study Details The study involved 180...

2015 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with more than 28,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees, and thank them for their time and ...

health-care policy
issues in oncology

Clinical Trial System Badly in Need of Overhaul, Say Panelists at Friends-Brookings Conference

Cancer clinical trials in three distinct phases, as they have been conducted for decades, are probably no longer the best way to bring a drug or biologic agent to market. This was the consensus of three panels at the 8th Annual Conference on Clinical Cancer Research convened by Friends of Cancer...

lung cancer
issues in oncology

Study Finds NSCLC to Be Genetically Different in Younger and Older Patients, Requiring Different Treatment Approaches

Unlike a number of other cancers in which young age at diagnosis is understood to represent distinct disease biology, the genomics and clinical characteristics of non–small cell lung cancer (NSCLC) in young patients are poorly understood. A study by Sacher et al investigating the relationship ...

Advertisement



Advertisement


Advertisement